223 related articles for article (PubMed ID: 36735057)
1. Two-year efficacy and safety of risdiplam in patients with type 2 or non-ambulant type 3 spinal muscular atrophy (SMA).
Oskoui M; Day JW; Deconinck N; Mazzone ES; Nascimento A; Saito K; Vuillerot C; Baranello G; Goemans N; Kirschner J; Kostera-Pruszczyk A; Servais L; Papp G; Gorni K; Kletzl H; Martin C; McIver T; Scalco RS; Staunton H; Yeung WY; Fontoura P; Mercuri E;
J Neurol; 2023 May; 270(5):2531-2546. PubMed ID: 36735057
[TBL] [Abstract][Full Text] [Related]
2. Safety and efficacy of once-daily risdiplam in type 2 and non-ambulant type 3 spinal muscular atrophy (SUNFISH part 2): a phase 3, double-blind, randomised, placebo-controlled trial.
Mercuri E; Deconinck N; Mazzone ES; Nascimento A; Oskoui M; Saito K; Vuillerot C; Baranello G; Boespflug-Tanguy O; Goemans N; Kirschner J; Kostera-Pruszczyk A; Servais L; Gerber M; Gorni K; Khwaja O; Kletzl H; Scalco RS; Staunton H; Yeung WY; Martin C; Fontoura P; Day JW;
Lancet Neurol; 2022 Jan; 21(1):42-52. PubMed ID: 34942136
[TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of risdiplam in patients with type 1 spinal muscular atrophy (FIREFISH part 2): secondary analyses from an open-label trial.
Masson R; Mazurkiewicz-Bełdzińska M; Rose K; Servais L; Xiong H; Zanoteli E; Baranello G; Bruno C; Day JW; Deconinck N; Klein A; Mercuri E; Vlodavets D; Wang Y; Dodman A; El-Khairi M; Gorni K; Jaber B; Kletzl H; Gaki E; Fontoura P; Darras BT;
Lancet Neurol; 2022 Dec; 21(12):1110-1119. PubMed ID: 36244364
[TBL] [Abstract][Full Text] [Related]
4. Risdiplam: A Review in Spinal Muscular Atrophy.
Paik J
CNS Drugs; 2022 Apr; 36(4):401-410. PubMed ID: 35284988
[TBL] [Abstract][Full Text] [Related]
5. Risdiplam-Treated Infants with Type 1 Spinal Muscular Atrophy versus Historical Controls.
Darras BT; Masson R; Mazurkiewicz-Bełdzińska M; Rose K; Xiong H; Zanoteli E; Baranello G; Bruno C; Vlodavets D; Wang Y; El-Khairi M; Gerber M; Gorni K; Khwaja O; Kletzl H; Scalco RS; Fontoura P; Servais L;
N Engl J Med; 2021 Jul; 385(5):427-435. PubMed ID: 34320287
[TBL] [Abstract][Full Text] [Related]
6. Risdiplam in Spinal Muscular Atrophy: Safety Profile and Use Through The Early Access to Medicine Scheme for the Paediatric Cohort in Great Britain.
Cornell N; Childs AM; Wraige E; Munot P; Ambegaonkar G; Chow G; Hughes I; Illingworth M; Majumdar A; Marini-Bettolo C; Parasuraman D; Spinty S; Willis T; Scoto M; Baranello G;
J Neuromuscul Dis; 2024; 11(2):361-368. PubMed ID: 38189761
[TBL] [Abstract][Full Text] [Related]
7. Risdiplam: an investigational survival motor neuron 2 (SMN2) splicing modifier for spinal muscular atrophy (SMA).
Markati T; Fisher G; Ramdas S; Servais L
Expert Opin Investig Drugs; 2022 May; 31(5):451-461. PubMed ID: 35316106
[TBL] [Abstract][Full Text] [Related]
8. Long-Term Comparative Efficacy and Safety of Risdiplam and Nusinersen in Children with Type 1 Spinal Muscular Atrophy.
Kokaliaris C; Evans R; Hawkins N; Mahajan A; Scott DA; Sutherland CS; Nam J; Sajeev G
Adv Ther; 2024 Jun; 41(6):2414-2434. PubMed ID: 38705943
[TBL] [Abstract][Full Text] [Related]
9. Short-term safety results from compassionate use of risdiplam in patients with spinal muscular atrophy in Germany.
Hahn A; Günther R; Ludolph A; Schwartz O; Trollmann R; Weydt P; Weiler M; Neuland K; Schwaderer MS; Hagenacker T;
Orphanet J Rare Dis; 2022 Jul; 17(1):276. PubMed ID: 35854272
[TBL] [Abstract][Full Text] [Related]
10. [Risdiplam for the treatment of spinal muscular atrophy].
Vlodavets DV
Zh Nevrol Psikhiatr Im S S Korsakova; 2024; 124(2):45-57. PubMed ID: 38465810
[TBL] [Abstract][Full Text] [Related]
11. Risdiplam in Type 1 Spinal Muscular Atrophy.
Baranello G; Darras BT; Day JW; Deconinck N; Klein A; Masson R; Mercuri E; Rose K; El-Khairi M; Gerber M; Gorni K; Khwaja O; Kletzl H; Scalco RS; Seabrook T; Fontoura P; Servais L;
N Engl J Med; 2021 Mar; 384(10):915-923. PubMed ID: 33626251
[TBL] [Abstract][Full Text] [Related]
12. A phase 1 healthy male volunteer single escalating dose study of the pharmacokinetics and pharmacodynamics of risdiplam (RG7916, RO7034067), a SMN2 splicing modifier.
Sturm S; Günther A; Jaber B; Jordan P; Al Kotbi N; Parkar N; Cleary Y; Frances N; Bergauer T; Heinig K; Kletzl H; Marquet A; Ratni H; Poirier A; Müller L; Czech C; Khwaja O
Br J Clin Pharmacol; 2019 Jan; 85(1):181-193. PubMed ID: 30302786
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of risdiplam in spinal muscular atrophy: A systematic review and meta-analysis.
Pascual-Morena C; Martínez-Vizcaíno V; Cavero-Redondo I; Martínez-García I; Moreno-Herráiz N; Álvarez-Bueno C; Saz-Lara A
Pharmacotherapy; 2024 Jan; 44(1):97-105. PubMed ID: 37574770
[TBL] [Abstract][Full Text] [Related]
14. Risdiplam in types 2 and 3 spinal muscular atrophy: A randomised, placebo-controlled, dose-finding trial followed by 24 months of treatment.
Mercuri E; Baranello G; Boespflug-Tanguy O; De Waele L; Goemans N; Kirschner J; Masson R; Mazzone ES; Pechmann A; Pera MC; Vuillerot C; Bader-Weder S; Gerber M; Gorni K; Hoffart J; Kletzl H; Martin C; McIver T; Scalco RS; Yeung WY; Servais L;
Eur J Neurol; 2023 Jul; 30(7):1945-1956. PubMed ID: 35837793
[TBL] [Abstract][Full Text] [Related]
15. Multidisciplinary team meetings in treatment of spinal muscular atrophy adult patients: a real-life observatory for innovative treatments.
Salort-Campana E; Solé G; Magot A; Tard C; Noury JB; Behin A; De La Cruz E; Boyer F; Lefeuvre C; Masingue M; Debergé L; Finet A; Brison M; Spinazzi M; Pegat A; Sacconi S; Malfatti E; Choumert A; Bellance R; Bedat-Millet AL; Feasson L; Vuillerot C; Jacquin-Piques A; Michaud M; Pereon Y; Stojkovic T; Laforêt P; Attarian S; Cintas P
Orphanet J Rare Dis; 2024 Jan; 19(1):24. PubMed ID: 38268028
[TBL] [Abstract][Full Text] [Related]
16. How does risdiplam compare with other treatments for Types 1-3 spinal muscular atrophy: a systematic literature review and indirect treatment comparison.
Ribero VA; Daigl M; Martí Y; Gorni K; Evans R; Scott DA; Mahajan A; Abrams KR; Hawkins N
J Comp Eff Res; 2022 Apr; 11(5):347-370. PubMed ID: 35040693
[No Abstract] [Full Text] [Related]
17. Risdiplam improves subjective swallowing quality in non-ambulatory adult patients with 5q-spinal muscular atrophy despite advanced motor impairment.
Brakemeier S; Lipka J; Schlag M; Kleinschnitz C; Hagenacker T
J Neurol; 2024 May; 271(5):2649-2657. PubMed ID: 38358553
[TBL] [Abstract][Full Text] [Related]
18. Risdiplam therapy in adults with 5q-SMA: observational study on motor function and treatment satisfaction.
Bjelica B; Wohnrade C; Cespedes I; Osmanovic A; Schreiber-Katz O; Petri S
BMC Neurol; 2024 Feb; 24(1):67. PubMed ID: 38368338
[TBL] [Abstract][Full Text] [Related]
19. Risdiplam treatment has not led to retinal toxicity in patients with spinal muscular atrophy.
Sergott RC; Amorelli GM; Baranello G; Barreau E; Beres S; Kane S; Mercuri E; Orazi L; SantaMaria M; Tremolada G; Santarsiero D; Waskowska A; Yashiro S; Denk N; Fürst-Recktenwald S; Gerber M; Gorni K; Jaber B; Jacobsen B; Mueller L; Nave S; Scalco RS; Marzoli SB;
Ann Clin Transl Neurol; 2021 Jan; 8(1):54-65. PubMed ID: 33231373
[TBL] [Abstract][Full Text] [Related]
20. JEWELFISH: 24-month results from an open-label study in non-treatment-naïve patients with SMA receiving treatment with risdiplam.
Chiriboga CA; Bruno C; Duong T; Fischer D; Mercuri E; Kirschner J; Kostera-Pruszczyk A; Jaber B; Gorni K; Kletzl H; Carruthers I; Martin C; Scalco RS; Fontoura P; Muntoni F;
J Neurol; 2024 May; ():. PubMed ID: 38733387
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
